EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals
Kirby McInerney LLP is investigating potential federal securities-law claims on behalf of EyePoint Pharmaceuticals (NASDAQ: EYPT) investors concerning possible violations by the company and/or its senior management; at this stage, no lawsuit has been filed. The probe follows EyePoint's August 14, 2026 topline disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial versus on-label aflibercept, after which the stock declined $9.88, or 67%, to close at $4.87 on August 17, 2026. The release recites earlier public statements of confidence in the trial results from President and CEO Jay S.
Key figures
- Stock decline pct
- 67%
- Stock decline usd
- 9.88
- Close price aug 17 2026
- 4.87
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.